CompletedPHASE1, PHASE2NCT03936426

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Studying Meningioma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Clarity Pharmaceuticals Ltd
Principal Investigator
Geoffrey Schembri, MD, MD, PHD
Royal North Shore Hospital
Intervention
Cu-64 SARTATE and Cu-67 SARTATE(drug)
Enrollment
5 enrolled
Eligibility
50 years · All sexes
Timeline
2018 – 2019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03936426 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma →

← Back to all trials